FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could
2023-11-01 07:48
US FTC sues to block Amgen's $27.8 billion deal for Horizon Therapeutics
By Diane Bartz and Leroy Leo WASHINGTON (Reuters) -The U.S. Federal Trade Commission said on Tuesday it has filed a
2023-05-17 05:25